Welcome to our dedicated page for Integer Hldgs SEC filings (Ticker: ITGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integer Holdings Corporation SEC filings document the disclosures of a NYSE-listed medical device CDMO with common stock trading under ITGR. Recent 8-K reports furnish quarterly and annual operating results, earnings-call materials, Regulation FD updates, capital-allocation actions, and material corporate events tied to the company’s medical device manufacturing business.
The filing record also covers governance and ownership matters, including definitive proxy materials, board composition, executive and director changes, committee assignments, compensation disclosures, shareholder meeting items, and cooperation-agreement terms with an investor group. These documents also disclose capital structure items such as common-stock registration details and share repurchase authorization.
Integer Holdings Corporation entered a cooperation agreement with investment firm Irenic on March 9, 2026, adding two independent directors to its Board. James F. Flanagan joins as a new company director and Aaron Kapito joins as an investor-designated director, both standing for election at the 2026 annual meeting.
Two current directors will not stand for re-election as part of a planned Board refresh, and the Board size will be limited to 13 members until the 2026 meeting and 11 members afterward during the cooperation period. Flanagan will serve on the Audit and Technology Strategy Committees, while Kapito will serve on the Compensation and Organization Committee and the Technology Strategy Committee. The agreement includes voting commitments, standstill and non-disparagement provisions through a period tied to the 2027 meeting nomination deadline or one year from the effective date, and Irenic has withdrawn its prior nomination and bylaw proposal. The company furnished a press release as an exhibit describing the agreement and appointments.
Integer Holdings Corp EVP and Chief Financial Officer Diron Smith reported equity compensation activity in Common Stock. On February 20, 2026, he acquired 798 and 817 shares at $0.00 per share from the vesting of performance-based restricted stock units tied to multi-year financial and relative total shareholder return goals. On the same date, 394 shares at $84.85 per share were disposed of to cover tax obligations, leaving him with 11,358.83 directly owned shares after these transactions.
Integer Holdings Corp executive Andrew Senn, President of Cardio & Vascular, reported equity compensation-related share movements. He acquired 2,340 and 2,380 shares of common stock through vesting of performance-based and relative total shareholder return PSUs after meeting multi-year financial and shareholder return goals. To cover tax obligations, 1,447 shares were disposed at $84.85 per share through a tax-withholding transaction. Following these transactions, he directly owned 14,813 common shares.
Integer Holdings Corp President & CEO Payman Khales reported multiple equity transactions involving performance-based awards and tax-related share dispositions. On February 24, 2026, 16,077 and 26,983 restricted stock units vested and converted into the same number of common shares after financial and relative total shareholder return goals were met.
These restricted stock units convert into common stock on a one-for-one basis. On the same date, 16,945 common shares at $87.10 were disposed of and on February 20, 2026, 4,638 shares at $84.85 were disposed of to satisfy tax obligations. Following these transactions, Khales directly owned 61,854 common shares.
Integer Holdings Corp executive Thomas Tommy P, VP and Corporate Controller, reported equity awards and related tax withholding in company stock. On February 20, 2026, he acquired 923 and 939 shares of common stock at $0.00 per share through grants classified as awards or other acquisitions.
The accompanying footnotes state these shares resulted from the vesting of performance-based restricted stock units tied to organic sales growth for 2023–2025 and separate units tied to three-year relative total shareholder return goals, for which vesting criteria were met. On the same date, 713 shares at $84.85 per share were disposed of in a transaction coded as a tax-withholding disposition, meaning shares were delivered to satisfy tax obligations rather than sold in an open-market trade.
Integer Holdings Corp executive Thor Kirk K, Chief Human Resources Officer, reported equity awards and a related tax share disposition in common stock.
He acquired 4,475 shares and 4,550 shares through vesting of performance-based PSUs tied to financial and relative total shareholder return goals, then disposed of 2,198 shares at $84.85 per share to satisfy tax obligations, leaving 34,982 shares owned directly.
Integer Holdings Corp reported that executive Jim Stephens, President, CRM & Neuro, acquired 2,691 shares of common stock through the vesting of performance-based restricted stock units. These units vested after meeting organic sales growth targets for 2023, 2024 and 2025. On the same date, 656 shares were disposed of at $84.85 per share to satisfy tax withholding obligations, leaving Stephens with 4,368 common shares held directly after the transactions.
Integer Holdings Corporation is a Plano, Texas–based medical device contract developer and manufacturer focused on Cardio & Vascular, Cardiac Rhythm Management and Neuromodulation markets. It operates as a pure-play medtech CDMO, supplying components, subassemblies and finished devices to large OEM customers worldwide.
In 2025, Integer completed three tuck-in acquisitions—Biocoat, VSi Parylene and Precision Coating—to deepen high-value coating and processing capabilities. Three major customers, Abbott Laboratories, Boston Scientific and Medtronic, each exceeded 10% of sales and together represented 49% of 2025 revenue. Backlog was approximately $675 million at December 31, 2025.
The company plans to exit its Portable Medical business by 2026 and emphasizes operational excellence through its Integer Operating and Production Systems. It highlights extensive global manufacturing, heavy regulation, cybersecurity exposure, raw-material and supply-chain risks, customer concentration, competitive pressure and evolving ESG and climate-related requirements as key risk factors.
Integer Holdings Corporation reported its fourth-quarter and full-year 2025 results, showing steady growth and higher profitability. Fourth-quarter sales rose 5% to $472 million, while adjusted EBITDA increased 11% to $106 million. GAAP diluted EPS from continuing operations grew 52% to $1.38 and adjusted EPS rose 23% to $1.76.
For full-year 2025, sales increased 8% to $1.854 billion. Adjusted operating income rose 13% to $321 million and adjusted net income grew 23% to $226 million, driving a 21% increase in adjusted EPS to $6.40. The company generated $196 million of operating cash flow, while total debt climbed to $1.185 billion, lifting its leverage ratio to 3.0x adjusted EBITDA.
Integer highlighted strong Cardio & Vascular growth, up 17% for the year to $1.107 billion, and continued intentional wind-down in Other Markets. The company repurchased 698,356 shares for $50 million in 2025 and plans an additional $50 million accelerated share repurchase under its existing authorization. For 2026, it forecasts sales of $1.826–$1.876 billion, GAAP diluted EPS of $3.53–$4.01 and adjusted EPS of $6.29–$6.78, with an adjusted effective tax rate of 16.0%–18.0%.
Integer Holdings Corp VP and Corporate Controller Tommy P. Thomas reported a series of equity compensation transactions. On January 16, 2026, he was granted 1,049 restricted stock units (RSUs), which vest in three equal annual installments beginning January 16, 2027. The RSUs convert into common stock on a one-for-one basis.
On January 17, 19 and 20, 2026, previously granted RSUs vested and were settled into common stock, with 218, 240 and 337 shares of common stock, respectively, reported as acquired at a price of $0 per share. To cover tax withholding on these vestings, he disposed of 193 shares at $85.78 per share on January 19, 2026 and 141 shares at $85.15 per share on January 20, 2026. Following these transactions, he directly owned 4,057 shares of Integer common stock.